{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:27:03Z","timestamp":1749061623604},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,2,19]],"date-time":"2011-02-19T00:00:00Z","timestamp":1298073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s12185-011-0782-2","type":"journal-article","created":{"date-parts":[[2011,2,18]],"date-time":"2011-02-18T04:42:13Z","timestamp":1298004133000},"page":"281-293","source":"Crossref","is-referenced-by-count":27,"title":["Immunotherapy for EBV-associated malignancies"],"prefix":"10.1007","volume":"93","author":[{"given":"Anna","family":"Merlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Turrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Dolcetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Zanovello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,19]]},"reference":[{"key":"782_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.semcancer.2008.10.008","volume":"18","author":"ME Ressing","year":"2008","unstructured":"Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ. Epstein\u2013Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol. 2008;18:397\u2013408.","journal-title":"Semin Cancer Biol."},{"key":"782_CR2","doi-asserted-by":"publisher","first-page":"e1122","DOI":"10.1371\/journal.pone.0001122","volume":"2","author":"J Li","year":"2007","unstructured":"Li J, Zeng XH, Mo HY, Rolen U, Gao YF, Zhang XS, Chen QY, Zhang L, Zeng MS, Li MZ, Huang WL, Wang XN, Zeng YX, Masucci MG. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One. 2007;2:e1122.","journal-title":"PLoS One"},{"key":"782_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","volume":"110","author":"MK Gandhi","year":"2007","unstructured":"Gandhi MK, Moll G, Smith C, Dua U, Lambley E, Ramuz O, Gill D, Marlton P, Seymour JF, Khanna R. Galectin-1 mediated suppression of Epstein\u2013Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007;110:1326\u20139.","journal-title":"Blood"},{"key":"782_CR4","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","volume":"25","author":"AD Hislop","year":"2007","unstructured":"Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein\u2013Barr virus. Annu Rev Immunol. 2007;25:587\u2013617.","journal-title":"Annu Rev Immunol."},{"key":"782_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299\u2013308.","journal-title":"Nat Rev Cancer."},{"key":"782_CR6","first-page":"501","volume":"84","author":"I Bourgault","year":"1991","unstructured":"Bourgault I, Gomez A, Gomard E, Levy JP. Limiting-dilution analysis of the HLA restriction of anti-Epstein\u2013Barr virus-specific cytolytic T lymphocytes. Clin Exp Immunol. 1991;84:501\u20137.","journal-title":"Clin Exp Immunol."},{"key":"782_CR7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1084\/jem.183.3.1215","volume":"183","author":"JF Lacerda","year":"1996","unstructured":"Lacerda JF, Ladanyi M, Louie DC, Fernandez JM, Papadopoulos EB, O\u2019Reilly RJ. Human Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 SCID\/SCID mice. J Exp Med. 1996;183:1215\u201328.","journal-title":"J Exp Med."},{"key":"782_CR8","first-page":"218","volume":"114","author":"TJ Boyle","year":"1993","unstructured":"Boyle TJ, Berend KR, DiMaio JM, Coles RE, Via DF, Lyerly HK. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery. 1993;114:218\u201325. (discussion 226).","journal-title":"Surgery"},{"key":"782_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0165-2478(96)02602-8","volume":"52","author":"RJ Buchsbaum","year":"1996","unstructured":"Buchsbaum RJ, Fabry JA, Lieberman J. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in SCID mice. Immunol Lett. 1996;52:145\u201352.","journal-title":"Immunol Lett."},{"key":"782_CR10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123\u201331.","journal-title":"Blood"},{"key":"782_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/TP.0b013e3181d7c424","volume":"90","author":"T Haque","year":"2010","unstructured":"Haque T, McAulay KA, Kelly D, Crawford DH. Allogeneic T-cell therapy for Epstein\u2013Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation. 2010;90:93\u20134.","journal-title":"Transplantation"},{"key":"782_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein\u2013Barr virus-related lymphoproliferation. Lancet. 1995;345:9\u201313.","journal-title":"Lancet"},{"issue":"5","key":"782_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925\u201335.","journal-title":"Blood"},{"key":"782_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN. Infusions of donor leukocytes to treat Epstein\u2013Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185\u201391.","journal-title":"N Engl J Med"},{"key":"782_CR15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","volume":"92","author":"CM Rooney","year":"1998","unstructured":"Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein\u2013Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549\u201355.","journal-title":"Blood"},{"key":"782_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428190400002202","volume":"46","author":"S Gottschalk","year":"2005","unstructured":"Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma. 2005;46:1\u201310.","journal-title":"Leuk Lymphoma"},{"key":"782_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-3-642-56352-2_15","volume":"159","author":"Z Liu","year":"2002","unstructured":"Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002;159:123\u201333.","journal-title":"Recent Results Cancer Res"},{"key":"782_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm0596-551","volume":"2","author":"HE Heslop","year":"1996","unstructured":"Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein\u2013Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551\u20135.","journal-title":"Nat Med."},{"key":"782_CR19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","volume":"7","author":"P Comoli","year":"2007","unstructured":"Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648\u201355.","journal-title":"Am J Transplant."},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2007.06.020","volume":"40","author":"P Comoli","year":"2008","unstructured":"Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein\u2013Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis. 2008;40:68\u201370.","journal-title":"Blood Cells Mol Dis."},{"key":"782_CR21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","volume":"95","author":"A Gustafsson","year":"2000","unstructured":"Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG. Epstein\u2013Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807\u201314.","journal-title":"Blood"},{"key":"782_CR22","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of solid organ transplant recipients with autologous Epstein\u2013Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942\u20139.","journal-title":"Blood"},{"key":"782_CR23","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","volume":"99","author":"P Comoli","year":"2002","unstructured":"Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Vigano M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R. Infusion of autologous Epstein\u2013Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592\u20138.","journal-title":"Blood"},{"key":"782_CR24","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.4049\/jimmunol.160.12.6204","volume":"160","author":"T Haque","year":"1998","unstructured":"Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K, Burroughs AK, Prentice HG, Crawford DH. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol. 1998;160:6204\u20139.","journal-title":"J Immunol."},{"key":"782_CR25","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","volume":"103","author":"HJ Wagner","year":"2004","unstructured":"Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979\u201381.","journal-title":"Blood"},{"key":"782_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.TP.0000129813.54517.25","volume":"78","author":"S Pakakasama","year":"2004","unstructured":"Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein\u2013Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation. 2004;78:755\u20137.","journal-title":"Transplantation"},{"key":"782_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.bmt.1700883","volume":"20","author":"S Imashuku","year":"1997","unstructured":"Imashuku S, Goto T, Matsumura T, Naya M, Yamori M, Hojo M, Hibi S, Todo S. Unsuccessful CTL transfusion in a case of post-BMT Epstein\u2013Barr virus-associated lymphoproliferative disorder (EBV-LPD). Bone Marrow Transplant. 1997;20:337\u201340.","journal-title":"Bone Marrow Transplant"},{"key":"782_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.V97.4.835","volume":"97","author":"S Gottschalk","year":"2001","unstructured":"Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM. An Epstein\u2013Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood. 2001;97:835\u201343.","journal-title":"Blood"},{"key":"782_CR29","doi-asserted-by":"crossref","unstructured":"Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein\u2013Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998;(23):89\u201393.","DOI":"10.1093\/oxfordjournals.jncimonographs.a024180"},{"key":"782_CR30","doi-asserted-by":"publisher","first-page":"10391","DOI":"10.1073\/pnas.96.18.10391","volume":"96","author":"R Khanna","year":"1999","unstructured":"Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglass J, Williams T, Elliott SL, Moss DJ. Activation and adoptive transfer of Epstein\u2013Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA. 1999;96:10391\u20136.","journal-title":"Proc Natl Acad Sci USA."},{"key":"782_CR31","doi-asserted-by":"publisher","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein\u2013Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005;23:8942\u20139.","journal-title":"J Clin Oncol."},{"key":"782_CR32","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1097\/01.TP.0000058745.02123.6F","volume":"75","author":"MA Sherritt","year":"2003","unstructured":"Sherritt MA, Bharadwaj M, Burrows JM, Morrison LE, Elliott SL, Davis JE, Kear LM, Slaughter RE, Bell SC, Galbraith AJ, Khanna R, Moss DJ. Reconstitution of the latent T-lymphocyte response to Epstein\u2013Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003;75:1556\u201360.","journal-title":"Transplantation"},{"key":"782_CR33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1046\/j.1365-2141.2002.03683.x","volume":"118","author":"Q Sun","year":"2002","unstructured":"Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol. 2002;118:799\u2013808.","journal-title":"Br J Haematol."},{"issue":"23","key":"782_CR34","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","volume":"114","author":"B Angelis De","year":"2009","unstructured":"De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM, Savoldo B. Generation of Epstein\u2013Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114(23):4784\u201391.","journal-title":"Blood"},{"issue":"23","key":"782_CR35","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","volume":"114","author":"J Brewin","year":"2009","unstructured":"Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, Pule M. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood. 2009;114(23):4792\u2013803.","journal-title":"Blood"},{"key":"782_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12026-007-0059-2","volume":"38","author":"RJ O\u2019Reilly","year":"2007","unstructured":"O\u2019Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res. 2007;38:237\u201350.","journal-title":"Immunol Res."},{"issue":"23","key":"782_CR37","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","volume":"116","author":"JN Barker","year":"2010","unstructured":"Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O\u2019Reilly RJ. Successful treatment of Epstein\u2013Barr virus (EBV)-associated post-transplant lymphoma after cord blood transplant using third-party EBV-specific cytotoxic T-lymphocytes. Blood. 2010;116(23):5045\u20139.","journal-title":"Blood"},{"key":"782_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1006\/clim.2000.4948","volume":"98","author":"R Hong","year":"2001","unstructured":"Hong R, Shen V, Rooney C, Hughes DP, Smith C, Comoli P, Zhang L. Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein\u2013Barr-specific cytotoxic T lymphocytes. Clin Immunol. 2001;98:54\u201361.","journal-title":"Clin Immunol."},{"key":"782_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1470-2045(05)70171-6","volume":"6","author":"RF Wynn","year":"2005","unstructured":"Wynn RF, Arkwright PD, Haque T, Gharib MI, Wilkie G, Morton-Jones M, Crawford DH. Treatment of Epstein\u2013Barr virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation. Lancet Oncol. 2005;6:344\u20136.","journal-title":"Lancet Oncol."},{"key":"782_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","volume":"90","author":"MJ Smyth","year":"2006","unstructured":"Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1\u201350.","journal-title":"Adv Immunol."},{"key":"782_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1084\/jem.176.1.157","volume":"176","author":"RJ Murray","year":"1992","unstructured":"Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein\u2013Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176:157\u201368.","journal-title":"J Exp Med."},{"key":"782_CR42","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.20040890","volume":"200","author":"CM Bollard","year":"2004","unstructured":"Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE, Cytotoxic T. Lymphocyte therapy for Epstein\u2013Barr virus+ Hodgkin\u2019s disease. J Exp Med. 2004;200:1623\u201333.","journal-title":"J Exp Med."},{"key":"782_CR43","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2008-02-142596","volume":"113","author":"J Klibi","year":"2009","unstructured":"Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Moulec SL, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein\u2013Barr virus-infected nasopharyngeal carcinoma cells. Blood. 2009;113:1957\u201366.","journal-title":"Blood"},{"key":"782_CR44","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1073\/pnas.0706017104","volume":"104","author":"P Juszczynski","year":"2007","unstructured":"Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104:13134\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"782_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.exphem.2005.11.008","volume":"34","author":"G Khan","year":"2006","unstructured":"Khan G. Epstein\u2013Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin\u2019s lymphoma? Exp Hematol. 2006;34:399\u2013406.","journal-title":"Exp Hematol."},{"key":"782_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.exphem.2007.01.030","volume":"35","author":"NA Marshall","year":"2007","unstructured":"Marshall NA, Culligan DJ, Tighe J, Johnston PW, Barker RN, Vickers MA. The relationships between Epstein\u2013Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin\u2019s lymphoma. Exp Hematol. 2007;35:596\u2013604.","journal-title":"Exp Hematol."},{"key":"782_CR47","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","volume":"99","author":"CM Bollard","year":"2002","unstructured":"Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J, Brenner MK, Heslop HE, Rooney CM. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179\u201387.","journal-title":"Blood"},{"key":"782_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/sj.cgt.7700664","volume":"11","author":"HJ Wagner","year":"2004","unstructured":"Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE, Rooney CM. A strategy for treatment of Epstein\u2013Barr virus-positive Hodgkin\u2019s disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004;11:81\u201391.","journal-title":"Cancer Gene Ther"},{"key":"782_CR49","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdh027","volume":"15","author":"P Comoli","year":"2004","unstructured":"Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P. Adoptive transfer of allogeneic Epstein\u2013Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol. 2004;15:113\u20137.","journal-title":"Ann Oncol."},{"key":"782_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.1430","volume":"94","author":"D Chua","year":"2001","unstructured":"Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW, Ng MH. Adoptive transfer of autologous Epstein\u2013Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 2001;94:73\u201380.","journal-title":"Int J Cancer"},{"key":"782_CR51","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of nasopharyngeal carcinoma with Epstein\u2013Barr virus-specific T lymphocytes. Blood. 2005;105:1898\u2013904.","journal-title":"Blood"},{"key":"782_CR52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010;33:983\u201390.","journal-title":"J Immunother."},{"issue":"Suppl 2","key":"782_CR53","first-page":"S39","volume":"81","author":"CM Rooney","year":"2002","unstructured":"Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin\u2019s disease. Ann Hematol. 2002;81(Suppl 2):S39\u201342.","journal-title":"Ann Hematol"},{"key":"782_CR54","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","volume":"91","author":"MA Roskrow","year":"1998","unstructured":"Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM. Epstein\u2013Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin\u2019s disease. Blood. 1998;91:2925\u201334.","journal-title":"Blood"},{"key":"782_CR55","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/10428190600604724","volume":"47","author":"CM Bollard","year":"2006","unstructured":"Bollard CM, Gottschalk S, Huls MH, Molldrem J, Przepiorka D, Rooney CM, Heslop HE. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47:837\u201342.","journal-title":"Leuk Lymphoma"},{"key":"782_CR56","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/cncr.20188","volume":"100","author":"KG Lucas","year":"2004","unstructured":"Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein\u2013Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892\u2013901.","journal-title":"Cancer"},{"key":"782_CR57","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1056\/NEJMoa032260","volume":"350","author":"JC Lin","year":"2004","unstructured":"Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS. Quantification of plasma Epstein\u2013Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461\u201370.","journal-title":"N Engl J Med."},{"key":"782_CR58","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood-2008-05-157222","volume":"113","author":"CU Louis","year":"2009","unstructured":"Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, Gee AP, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009;113:2442\u201350.","journal-title":"Blood"},{"key":"782_CR59","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233\u20139.","journal-title":"J Clin Oncol."},{"key":"782_CR60","unstructured":"Chan J, Jaffe ES, Ralfkiaer E. Extranodal NK\/T cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 204\u20138."},{"key":"782_CR61","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/blood-2002-01-0039","volume":"100","author":"B Savoldo","year":"2002","unstructured":"Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, (2002) Webster-Cyriaque J, Gee AP, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein\u2013Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059\u201366.","journal-title":"Blood"},{"key":"782_CR62","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF02983242","volume":"78","author":"M Hagihara","year":"2003","unstructured":"Hagihara M, Tsuchiya T, Hyodo O, Ueda Y, Tazume K, Masui A, Kanemura A, Yoshiba F, Takashimizu S, Matzusaki S, Kato S, Hotta T. Clinical effects of infusing anti-Epstein\u2013Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection. Int J Hematol. 2003;78:62\u20138.","journal-title":"Int J Hematol."},{"key":"782_CR63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1046\/j.1365-2249.1996.d01-619.x","volume":"103","author":"K Kuzushima","year":"1996","unstructured":"Kuzushima K, Yamamoto M, Kimura H, Ando Y, Kudo T, Tsuge I, Morishima T. Establishment of anti-Epstein\u2013Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol. 1996;103:192\u20138.","journal-title":"Clin Exp Immunol."},{"key":"782_CR64","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1532\/IJH97.A30505","volume":"83","author":"HI Cho","year":"2006","unstructured":"Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC, Kim TG. Adoptive transfer of Epstein\u2013Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006;83:66\u201373.","journal-title":"Int J Hematol."},{"key":"782_CR65","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1182\/blood-2010-06-292268","volume":"116","author":"CP Fox","year":"2010","unstructured":"Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O\u2019Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M. A novel latent membrane 2 transcript expressed in Epstein\u2013Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010;116:3695\u2013704.","journal-title":"Blood"},{"key":"782_CR66","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","volume":"110","author":"CM Bollard","year":"2007","unstructured":"Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838\u201345.","journal-title":"Blood"},{"key":"782_CR67","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1349-7006.2008.00852.x","volume":"99","author":"A Demachi-Okamura","year":"2008","unstructured":"Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K. Epstein\u2013Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein\u2013Barr virus-carrying natural killer and T cells. Cancer Sci. 2008;99:1633\u201342.","journal-title":"Cancer Sci."},{"key":"782_CR68","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1158\/0008-5472.CAN-07-3212","volume":"68","author":"H Kobayashi","year":"2008","unstructured":"Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res. 2008;68:901\u20138.","journal-title":"Cancer Res"},{"key":"782_CR69","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/ijc.23845","volume":"123","author":"KN Heller","year":"2008","unstructured":"Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, Munz C. Patients with Epstein\u2013Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123:2824\u201331.","journal-title":"Int J Cancer"},{"key":"782_CR70","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ijc.24014","volume":"124","author":"AM Moormann","year":"2009","unstructured":"Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Munz C, Rochford R. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer. 2009;124:1721\u20136.","journal-title":"Int J Cancer"},{"key":"782_CR71","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20040191","volume":"199","author":"J Tellam","year":"2004","unstructured":"Tellam J, Connolly G, Green KJ, Miles JJ, Moss DJ, Burrows SR, Khanna R. Endogenous presentation of CD8+ T cell epitopes from Epstein\u2013Barr virus-encoded nuclear antigen 1. J Exp Med. 2004;199:1421\u201331.","journal-title":"J Exp Med."},{"key":"782_CR72","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.20031219","volume":"199","author":"KS Voo","year":"2004","unstructured":"Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein\u2013Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med. 2004;199:459\u201370.","journal-title":"J Exp Med."},{"key":"782_CR73","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/blood-2010-03-274076","volume":"116","author":"K Jones","year":"2010","unstructured":"Jones K, Nourse JP, Morrison L, Nguyen-Van D, Moss DJ, Burrows SR, Gandhi MK. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood. 2010;116:2245\u201352.","journal-title":"Blood"},{"key":"782_CR74","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.4049\/jimmunol.0803572","volume":"182","author":"KA McAulay","year":"2009","unstructured":"McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH. Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J Immunol. 2009;182:3892\u2013901.","journal-title":"J Immunol."},{"key":"782_CR75","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","volume":"21","author":"P Muranski","year":"2009","unstructured":"Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21:200\u20138.","journal-title":"Curr Opin Immunol."},{"issue":"10","key":"782_CR76","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.4049\/jimmunol.0902850","volume":"184","author":"A Merlo","year":"2010","unstructured":"Merlo A, Turrini R, Bobisse S, Zamarchi R, Alaggio R, Dolcetti R, Mautner J, Zanovello P, Amadori A, Rosato A. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors. J Immunol. 2010;184(10):5895\u2013902.","journal-title":"J Immunol"},{"key":"782_CR77","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/eji.200324794","volume":"34","author":"J Mautner","year":"2004","unstructured":"Mautner J, Pich D, Nimmerjahn F, Milosevic S, Adhikary D, Christoph H, Witter K, Bornkamm GW, Hammerschmidt W, Behrends U. Epstein\u2013Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol. 2004;34:2500\u20139.","journal-title":"Eur J Immunol."},{"key":"782_CR78","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1371\/journal.pone.0000583","volume":"2","author":"D Adhikary","year":"2007","unstructured":"Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J. Immunodominance of lytic cycle antigens in Epstein\u2013Barr virus-specific CD4+ T cell preparations for therapy. PLoS One. 2007;2:e583.","journal-title":"PLoS One"},{"key":"782_CR79","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20051287","volume":"203","author":"D Adhikary","year":"2006","unstructured":"Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J. Control of Epstein\u2013Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006;203:995\u20131006.","journal-title":"J Exp Med."},{"key":"782_CR80","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/blood-2008-12-194043","volume":"114","author":"HM Long","year":"2009","unstructured":"Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein\u2013Barr virus-transformed B cells. Blood. 2009;114:807\u201315.","journal-title":"Blood"},{"key":"782_CR81","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1182\/blood-2009-07-234906","volume":"115","author":"AL Amir","year":"2010","unstructured":"Amir AL, D\u2019Orsogna LJ, Roelen DL, van Loenen MM, Hagedoorn RS, de Boer R, van der Hoorn MA, Kester MG, Doxiadis II, Falkenburg JH, Claas FH, Heemskerk MH. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115:3146\u201357.","journal-title":"Blood"},{"issue":"22","key":"782_CR82","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","volume":"116","author":"JJ Melenhorst","year":"2010","unstructured":"Melenhorst JJ, Leen AM, Bollard CM, Quigley MF, Price DA, Rooney CM, Brenner MK, Barrett AJ, Heslop HE. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700\u20132.","journal-title":"Blood"},{"key":"782_CR83","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.4049\/jimmunol.177.3.1427","volume":"177","author":"E Landais","year":"2006","unstructured":"Landais E, Morice A, Long HM, Haigh TA, Charreau B, Bonneville M, Taylor GS, Houssaint E. EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol. 2006;177:1427\u201333.","journal-title":"J Immunol."},{"key":"782_CR84","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616\u201326.","journal-title":"J Clin Invest."},{"key":"782_CR85","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri1842","volume":"6","author":"L Gattinoni","year":"2006","unstructured":"Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383\u201393.","journal-title":"Nat Rev Immunol."},{"key":"782_CR86","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","volume":"111","author":"CS Hinrichs","year":"2008","unstructured":"Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. 2008;111:5326\u201333.","journal-title":"Blood"},{"key":"782_CR87","doi-asserted-by":"publisher","first-page":"17469","DOI":"10.1073\/pnas.0907448106","volume":"106","author":"CS Hinrichs","year":"2009","unstructured":"Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA. 2009;106:17469\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"782_CR88","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2008-05-156059","volume":"113","author":"S Kaneko","year":"2009","unstructured":"Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L, Radrizzani M, La Seta-Catamancio S, Provasi E, Mondino A, Nagasawa T, Fleischhauer K, Russo V, Traversari C, Ciceri F, Bordignon C, Bonini C. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009;113:1006\u201315.","journal-title":"Blood"},{"key":"782_CR89","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.coi.2010.01.020","volume":"22","author":"MK Brenner","year":"2010","unstructured":"Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251\u20137.","journal-title":"Curr Opin Immunol."},{"key":"782_CR90","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1365-2567.2008.03035.x","volume":"127","author":"VJ Vanhoutte","year":"2009","unstructured":"Vanhoutte VJ, McAulay KA, McCarrell E, Turner M, Crawford DH, Haque T. Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein\u2013Barr virus-specific cytotoxic T lymphocytes. Immunology. 2009;127:577\u201386.","journal-title":"Immunology"},{"key":"782_CR91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00002371-200407000-00007","volume":"27","author":"GM Wilkie","year":"2004","unstructured":"Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH, Haque T. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein\u2013Barr virus-associated diseases. J Immunother. 2004;27:309\u201316.","journal-title":"J Immunother"},{"issue":"14","key":"782_CR92","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","volume":"115","author":"A Moosmann","year":"2010","unstructured":"Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, Mautner J, Hammerschmidt W, Schendel DJ, Kolb HJ. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960\u201370.","journal-title":"Blood"},{"key":"782_CR93","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","volume":"114","author":"PJ Hanley","year":"2009","unstructured":"Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114:1958\u201367.","journal-title":"Blood"},{"key":"782_CR94","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1182\/blood-2009-09-242263","volume":"115","author":"KP Micklethwaite","year":"2010","unstructured":"Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010;115:2695\u2013703.","journal-title":"Blood"},{"key":"782_CR95","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nm1475","volume":"12","author":"AM Leen","year":"2006","unstructured":"Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160\u20136.","journal-title":"Nat Med."},{"issue":"19","key":"782_CR96","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","volume":"114","author":"AM Leen","year":"2009","unstructured":"Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein\u2013Barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood. 2009;114(19):4283\u201392.","journal-title":"Blood"},{"key":"782_CR97","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","volume":"14","author":"MA Pule","year":"2008","unstructured":"Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264\u201370.","journal-title":"Nat Med."},{"key":"782_CR98","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/nm1108-1148","volume":"14","author":"RJ O\u2019Reilly","year":"2008","unstructured":"O\u2019Reilly RJ. Epstein\u2013Barr virus sustains tumor killers. Nat Med. 2008;14:1148\u201350.","journal-title":"Nat Med."},{"key":"782_CR99","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3324\/haematol.2010.023689","volume":"95","author":"A Merlo","year":"2010","unstructured":"Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P, Rosato A. The interplay between Epstein\u2013Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010;95:1769\u201377.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-011-0782-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0782-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-011-0782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:07:08Z","timestamp":1685952428000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-011-0782-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,19]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s12185-011-0782-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,19]]}}}